Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia

Mallette M. Asmuth, MD, Anna B. Halpern, MD, Megan Othus, PhD, Emily Huebner, MS, Carole M. Shaw, BA, Kelda Gardner, PA-C, Elihu H. Estey, MD, Roland B. Walter, MDPhDMS, Colin D. Godwin, MDMPhil

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-142730

Published: 2020

Journal Articles

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Jacob Appelbaum, MD PhD, Anisha Loeb, BA, Kelda Gardner, PA-C, Carole M. Shaw, BA, Paul C. Hendrie, MD PhD, Colin D. Godwin, MDMPhil, Mary-Elizabeth M. Percival, MD, Anna B. Halpern, MD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Michael C. Jensen, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 260.

https://doi.org/10.1182/blood-2019-131678

Published: 2019

Journal Articles

Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS

Kelda Gardner, PA-C, Megan Othus, PhD, Carole M. Shaw, BA, Pamela S. Becker, MD PhD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 5093.

https://doi.org/10.1182/blood-2019-130965

Published: 2019

Journal Articles

AML Clinical Trial Decision Making: How Often Do Physicians Follow a Consensus-Derived Assignment Scheme?

Kelda Gardner, PA-C, Mary-Elizabeth M. Percival, MD, Paul C. Hendrie, MD PhD, Anna B. Halpern, MD, Carole M. Shaw, BA, Jacob Appelbaum, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 5094.

https://doi.org/10.1182/blood-2019-131280

Published: 2019

Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Blood (2019) 134 (Supplement_1): 1269.

https://doi.org/10.1182/blood-2019-130996

Published: 2019

Journal Articles

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Noam E. Kopmar, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Roland B. Walter, MDPhDMS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 2214.

https://doi.org/10.1182/blood-2019-123315

Published: 2019

Journal Articles

Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Genevieve Alcorn, Mary-Elizabeth M. Percival, MD, Emily M Huebner, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Vivian G. Oehler, MD, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1364.

https://doi.org/10.1182/blood-2019-123542

Published: 2019

Journal Articles

E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML

Sylvia S Chien, Jin Dai, PhD, John L Magnani, PhD, Taylor S Sekizaki, William E Fogler, PhD, Helen M Thackray, MD, Kelda Gardner, PA-C, Elihu H. Estey, MD, Pamela S Becker, MD PhD

Blood (2018) 132 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2018-99-119449

Published: 2018

Journal Articles

A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2016) 128 (22): 4043.

https://doi.org/10.1182/blood.V128.22.4043.4043

Published: 2016

Journal Articles

Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly AML or High Risk MDS Patients

Kelda Gardner, PA-C, MHS, Elihu H. Estey, MD, Weigang Tong, MD, Robert McCroskey, MD, Roland B. Walter, MD PhD MS, Paul C. Hendrie, MD PhD, Bart L. Scott, MD MS, Andrea M. Perdue, PA-C, Mary-Elizabeth M. Percival, MD MS, Heather A. Smith, PA-C, Cody Hammer, Pamela S. Becker, MD PhD

Blood (2016) 128 (22): 5207.

https://doi.org/10.1182/blood.V128.22.5207.5207

Published: 2016

NARROW

Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS

AML Clinical Trial Decision Making: How Often Do Physicians Follow a Consensus-Derived Assignment Scheme?

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML

A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia

Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly AML or High Risk MDS Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only